Castle Biosciences, Inc. (NASDAQ:CSTL)
About the company
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Gross Margin (in %)
Operating Margin (in %)
Net Margin (in %)
Dividend Yield (in %)
|Name||Ticker||Market capitalization (in USD Million)||Revenues (in USD Million)||Price/Book||Price/Earning||Net margin (in %)|
|Guardant Health, Inc.||GH||7770.15||245.00||10.52||-100.66||-31.53|
|LHC Group, Inc.||LHCG||5518.93||2091.00||3.93||56.16||4.73|
|1Life Healthcare, Inc.||ONEM||4827.06||292.00||10.38||-60.81||-27.31|
|The Ensign Group, Inc.||ENSG||2376.08||2155.00||3.37||19.20||5.76|
|Acadia Healthcare Co., Inc.||ACHC||2250.16||3130.00||0.92||19.98||3.61|
|Addus HomeCare Corp.||ADUS||1289.96||598.00||3.05||62.68||3.33|
|U.S. Physical Therapy, Inc.||USPH||1051.18||478.00||4.31||35.78||6.03|
|Castle Biosciences, Inc.||CSTL||665.04||61.00||7.72||652.00||9.75|
|The Pennant Group, Inc.||PNTG||640.64||352.00||8.38||152.53||1.19|
|Option Care Health, Inc.||OPCH||627.36||2539.00||2.65||-6.41||-3.63|
|Tivity Health, Inc.||TVTY||540.00||1255.00||70.31||-1.09||-38.98|
|Fulgent Genetics, Inc.||FLGT||324.20||35.00||4.32||-1621.00||-1.31|
|American Renal Associates Holdings, Inc.||ARA||205.12||824.00||-2.54||-11.45||-2.19|
|CRH Medical Corp.||CRHM||164.62||117.00||2.17||112.75||1.52|
|Guardion Health Sciences, Inc.||GHSI||36.63||1.00||2.69||-1.60||-824.43|
|Cardiff Oncology, Inc.||CRDF||30.17||0.00||12.31||-1.97||-883.77|
|OncoSec Medical, Inc.||ONCS||25.61||None||2.10||-0.68||None|
|Capital Senior Living Corp.||CSU||21.60||439.00||-0.69||-0.31||-16.00|
|American Shared Hospital Services||AMS||12.66||20.00||0.46||52.75||1.28|
|IMAC Holdings, Inc.||IMAC||10.98||16.00||1.26||-1.63||-42.30|
Latest insider transactions
|Date||Role||Name||Transaction||Quantity||Quantity Owned After|
In this article we will check out the progression of hedge fund sentiment towards Castle Biosciences, Inc. (NASDAQ:CSTL) and ...
Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that the underwriters of its recently closed underwritten public offering of ...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 2,000,000 shares of its common ...
Squarepoint Ops LLC cut its holdings in shares of Castle Biosciences (NASDAQ:CSTL) by 52.8% during the first quarter, ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering of 1,500,000 shares of its common stock.
Castle Biosciences, Inc. (NASDAQ:CSTL), announced today the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $37.00 per share.
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering of 1,500,000 shares of its common stock. Castle Biosciences also intends to ...